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Alessandro Giuffrè; alessandro.giuffre@uniroma1.it
Received 9 December 2016; Revised 10 January 2017; Accepted 16 January 2017; Published 22 March 2017
Academic Editor: Steven McAnulty
Copyright © 2017 João B. Vicente et al.This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The human disease classical homocystinuria results from mutations in the gene encoding the pyridoxal 5󸀠-phosphate- (PLP-)
dependent cystathionine 𝛽-synthase (CBS), a key enzyme in the transsulfuration pathway that controls homocysteine levels, and
is a major source of the signaling molecule hydrogen sulfide (H2S). CBS activity, contributing to cellular redox homeostasis, is
positively regulated by s-adenosyl-l-methionine (AdoMet) but fully inhibited upon CO or NO∙ binding to a noncatalytic heme
moiety. Despite extensive studies, the molecular basis of several pathogenic CBS mutations is not yet fully understood. Here we
found that the ferrous heme of the reportedly mild p.P49L CBS variant has altered spectral properties and markedly increased
affinity forCO,making the proteinmuchmore prone thanwild type (WT)CBS to inactivation at physiological CO levels.Thehigher
CO affinity could result from the slightly higher flexibility in the heme surroundings revealed by solving at 2.80-Å resolution the
crystallographic structure of a truncated p.P49L.Additionally, we report that p.P49L displays impairedH2S-generating activity, fully
rescued by PLP supplementation along the purification, despite aminor responsiveness to AdoMet. Altogether, the results highlight
how increased propensity to CO inactivation of an otherwise WT-like variant may represent a novel pathogenic mechanism in
classical homocystinuria.
1. Introduction
Hydrogen sulfide (H2S) has emerged as a key signaling
molecule in human physiology and pathophysiology, being
implicated in the regulation of several processes such as
neuromodulation, angiogenesis, vasorelaxation, bioenerget-
ics/respiration, cell survival, and proliferation [1–4]. The gas
has a pivotal role in the control of cellular redox homeostasis
and prevention of oxidative stress, modulating the expression
of key antioxidant enzymes [2]. Similarly to other relevant
gaseous signaling molecules like CO and NO∙, at low con-
centrations H2S can exert cytoprotective effects or become
cytotoxic at higher concentrations.
At least three human enzymes have been identified as
key endogenous sources of H2S: cystathionine 𝛽-synthase
(CBS) and cystathionine 𝛾-lyase (CSE), both occurring in
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the transsulfuration pathway of methionine metabolism and
mercaptopyruvate sulfurtransferase (MST) [1]. Beyond ena-
bling conversion of homocysteine to cysteine through their
historically recognized canonical activities, CBS and CSE
catalyze a number of “alternative” reactions leading to
H2S synthesis, which has brought these enzymes into the
limelight [1, 5, 6]. Indeed, a growing number of human
pathologies, from cardiovascular and neurodegenerative dis-
eases to different cancer types, are reportedly associated
with disturbances of H2S metabolism related to CBS, CSE,
and/or MST [7]. CBS, in particular, has been shown to
be overexpressed in colorectal, ovarian, and breast cancer,
among other cancer types (reviewed in [8, 9]), as well as in
neurodegenerative diseases, such as amyotrophic lateral scle-
rosis [10]. The enzyme is therefore currently recognized as a
drug target [8].
CBS catalyzes the condensation of homocysteine and
serine (or cysteine) leading to formation of cystathionine
and H2O (or H2S). The human enzyme is a 551-amino acid
protein with a central catalytic domain, harboring a pyri-
doxal 5󸀠-phosphate (PLP) cofactor, flanked by a C-terminal
domain with a binding site for the allosteric positive regu-
lator s-adenosyl-l-methionine (AdoMet) and an N-terminal
domain, harboring a hexacoordinate hemewith C52 andH65
as endogenous Fe ligands [11]. Structural studies have shown
that whereas the AdoMet-binding domain occludes the sub-
strate entry site in the catalytic core, AdoMet binding induces
a conformational change clearing the path for substrates to
access the active site [11–13]. In the presence of AdoMet
enzymatic activity thus increases 2–5-fold, as measured with
isolated proteins and bacterial or human cell lysates. Another
interesting regulatory mechanism concerns the B-type heme
moiety in the N-terminal domain. While the enzyme is fully
active when the heme is in the oxidized state, reduction to
the ferrous state negatively impacts enzyme activity, possibly
through a ligand exchange mechanism involving the replace-
ment of C52 by a yet unknown neutral ligand [14, 15]. Such
change in the Fe coordination is accompanied by a notable
shift in the CBS heme Soret band from449 to 424 nm, leading
to an inactive protein species commonly referred to as “C-
424” [15]. Evenmore striking is that binding of NO∙ or CO to
the ferrous heme results in enzyme inhibition [16–20], with
different lines of evidence pointing to a physiological role
of this regulatory mechanism in vivo [21–27]. According to
structural and mutagenesis studies, changes in the heme
redox and ligation state are communicated to the PLP active
site through 𝛼-helix 8 [15, 28, 29].This regulatorymechanism
places CBS at the crossroad between the signaling pathways
of the three gasotransmitters (H2S, CO, and NO∙) in human
physiology [30]. More recently, it has been shown that
AdoMet enhances CBS sensitivity to CO and NO∙, further
highlighting an intricate interplay between the three domains
in the protein [20].
Classical homocystinuria (OMIM #236200) is an inborn
error of metabolism associated with mutations in the CBS
gene. With a variable incidence of 1 : 1,800 to 1 : 900,000, clas-
sical homocystinuria is biochemically detected by markedly
high homocysteine and methionine levels in plasma and
urine, with clinical presentation involving mental impair-
ment, vascular complications, dislocated lenses, and skeletal
abnormalities [31]. Notably, elevated homocysteine levels are
associated with oxidative stress conditions, well known to
contribute to the onset and progress of a broad spectrum of
diseases. Thus far, besides dietary methionine restriction,
the major therapeutic approach for classical homocystinuria
consists of administration of pyridoxine (vitamin B6), a
precursor of the PLP cofactor [31], although a significant
part of patients (approximately half) do not respond to this
treatment [32]. The vast majority of the mutations identified
in patients with classical homocystinuria are missense muta-
tions resulting in single amino acid substitutions. Whereas
most mutations affect the enzyme folding and/or activity [15,
28, 33–39], some of them have been shown to affect enzyme
regulation by AdoMet, pointing to such dysregulation as a
new pathogenicmechanism in classical homocystinuria [40].
The fact that several variants have impaired activity due to
protein misfolding is underlined by the demonstration that
some of them are amenable to be functionally rescued by
chemical chaperones [34, 36, 38, 39, 41, 42]. A novel ther-
apeutic approach is currently under development based on
enzyme replacement therapy using PEGylated recombinant
CBS, which has been shown to afford a marked decrease in
circulating homocysteine in a mouse model of homocystin-
uria [43]. This therapeutic approach might be particularly
relevant for PLP-unresponsive patients.
The 146 C>T transition in exon 1 of the CBS gene
generates the clinically relevant p.P49L variant, identified in
patients with classical homocystinuria [44–46].Themutation
results in mild to moderate symptoms and sporadic respon-
siveness to vitamin B6 treatment. When assayed in cell
extracts or after purification, the protein variant shows
impaired or wild type- (WT-) like canonical activity in the
absence or presence of PLP in the assays, respectively, and
milder to normal responsiveness to AdoMet [36, 37, 39,
40]. These findings point to defects in PLP incorporation,
although the protein variant as purified after recombinant
expression in Escherichia coli in the presence of suitable
chemical chaperones at optimal concentrations exhibits unaf-
fected PLP and heme incorporation, and unperturbed circu-
lar dichroism (CD) or UV-visible absorption spectra in the
oxidized state [39].
Herein we demonstrate that the p.P49L variant of human
CBS displays H2S-synthesizing activity largely sensitive to
PLP supplementation along the protein purification. The
crystallographic structure of a truncated version of CBS
p.P49L, devoid of the C-terminal AdoMet binding domain,
reveals no major differences at the level of the PLP catalytic
site with respect to theWTbut slightly increased protein flex-
ibility in the heme surroundings. As a novel finding we report
a markedly increased CO affinity of p.P49L as compared to
the wild type enzyme, en route to enzyme inactivation. The
obtained functional and structural data are discussed in light
of the proposal that in pathogenic variants of human CBS
increased reactivity towards exogenous ligands, such as CO,
represents a further molecular mechanism at the basis of
classical homocystinuria.
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2. Materials and Methods
2.1. Protein Expression and Purification. Recombinant full-
length human CBS p.P49L was expressed and purified as
previously described for WT CBS [19] in either the absence
or presence of 20𝜇M PLP, using the herein named pET28b-
CBS-p.P49L vector generated in [40]. With this vector as
template, site-directed mutagenesis was employed to obtain
also a truncated form of the protein (denoted by CBSΔ 409–551
p.P49L) devoid of the C-terminal 143 residues correspond-
ing to the AdoMet-binding domain. The 1227G>A mutant
(cDNA numbering) carrying a premature stop codon at
position 409 was generated from pET28b-CBS-p.P49L using
the XL Quick Change Kit (Agilent) and the primers 5󸀠-
GAAGAAGCCCTGGTGATGGCACCTCCGTG (forward)
and 5󸀠-CACGGAGGTGCCATCACCAGGGCTTCTTC (re-
verse). All vectors were checked for the correct mutation by
DNAsequencing. Expression andpurification ofCBSΔ 409–551
p.P49L were carried out as described in [20].
Purity of the isolated proteins was assessed by SDS-
PAGE and their concentration was determined by the Brad-
ford method [47], whereas the heme concentration in the
isolated oxidized proteins was determined using 𝜀428 nm =
92,700M−1 cm−1 [48].
Unless otherwise stated, the experiments were carried
out in 50mM KPi buffer, 300mM KCl, 10% glycerol, 100 𝜇M
EDTA, pH 7.0 (buffer A).
2.2. 𝐻2S Synthesis Assays. H2S production by recombinant
human CBS variants was measured at 37∘C, either by amper-
ometry using a H2S-selective electrode (World Precision
Instruments) or by the lead acetate method [5]. Purified
CBS (0.5–1𝜇M) was incubated for 10 minutes with 50𝜇M
PLP, 260U/ml catalase, and 0.4–2.0mMhomocysteine in the
absence or presence of 0.5mM AdoMet, after which 10mM
cysteine was added to trigger the reaction. Amperometric
assays were performed using an ISO-H2S-2 hydrogen sulfide
sensor coupled to an Apollo 4000 Free Radical Analyzer
(World Precision Instruments). After recording H2S produc-
tion for 3 minutes, the electrode was internally calibrated by
adding 4 𝜇M NaHS (corresponding to 2𝜇M H2S at pH 7.0).
Finally, 50𝜇M o-acetylserine and 200 nM Entamoeba his-
tolytica o-acetylserine sulfhydrylase were added to the reac-
tion mixture to remove H2S from solution and bring the
signal back to baseline [49]. Activity assays by the lead acetate
method were carried out in a thermostated cuvette under
stirring, according to [5]. Lead acetate (400 𝜇M) was added
to the reaction mix prior to cysteine addition and H2S pro-
duction monitored at 390 nm in an Agilent Cary-60 spectro-
photometer.
2.3. CO Titrations. UV-visible absorption spectra of oxidized
and reducedCBS p.P49L andWTwere recorded in anAgilent
Cary-60 spectrophotometer. Anaerobic titrations of reduced
CBS p.P49L with CO were performed at 20∘C in an Agilent
Cary-60 or a Shimadzu UVPC-1800 spectrophotometer. Gas
exchange was prevented either by filling the quartz cuvette
and sealing it with a rubber-cap or by adding mineral oil
on top of the aqueous medium. Anaerobic conditions were
ensured by nitrogen flushing and addition of glucose oxidase
(4 units⋅ml−1), catalase (13𝜇g⋅ml−1), superoxide dismutase
(12 units⋅ml−1), and glucose (3mM) to scavenge contaminant
oxygen, hydrogen peroxide, and superoxide anion. CBS
p.P49L and WT (1.4–1.6 𝜇M in heme) were reduced with
90 𝜇M sodium dithionite, diluted from a 45mM stock solu-
tion (quantitated using 𝜀314 nm = 8,043M−1⋅cm−1 [50]). CO
stock solutions were prepared by equilibrating thoroughly
degassed buffer A with the pure gas at 1 atm, yielding 1mM
CO at 20∘C. After each CO addition with gas-tight Hamilton
syringes, the spectral changes were visually inspected in real
time and a new addition was immediately made when no
more changes were observed.
According to [16, 19, 20, 51], two apparent 𝐾𝑑 (𝐾𝑑1 and𝐾𝑑2) were used to satisfactorily fit the CO affinity data. The𝐾𝑑1 and 𝐾𝑑2 values were obtained by fitting the data to (1),
where 𝑃𝐿 is the concentration of CO-bound CBS p.P49L,𝑃𝑇 and 𝐿𝑇 are, respectively, the total CBS p.P49L and CO
concentrations, and 𝛼1 and 𝛼2 are, respectively, the protein
fractions binding CO at higher (𝐾𝑑1) and lower (𝐾𝑑2) affinity.
𝑃𝐿 =
𝛼1 [(𝑃𝑇 + 𝐿𝑇 + 𝐾𝑑1) − √(𝑃𝑇 + 𝐿𝑇 + 𝐾𝑑1)2 − 4𝑃𝑇𝐿𝑇] + 𝛼2 [(𝑃𝑇 + 𝐿𝑇 + 𝐾𝑑2) − √(𝑃𝑇 + 𝐿𝑇 + 𝐾𝑑2)2 − 4𝑃𝑇𝐿𝑇]
2 .
(1)
2.4. Stopped-Flow Measurements. Time-resolved absorption
spectroscopy experiments were carried out in a thermostated
stopped-flow instrument (DX.17MV, Applied Photophysics),
equipped with a photodiode-array (light path, 1 cm). To
avoid light-induced artifacts, the intensity of the white-light
incident beam was decreased and a filter cutting UV light at
𝜆 < 360 nmwas employed. Absorption spectra were recorded
with an acquisition time of 10ms per spectrum according to
a logarithmic time scale. All reactions were carried out at
25∘C in buffer A. CBS p.P49L was thoroughly flushed with
nitrogen, after which glucose oxidase (4 units⋅ml−1), catalase
(13 𝜇g⋅ml−1), superoxide dismutase (12 units⋅ml−1), and glu-
cose (3mM) were added to scavenge oxygen, hydrogen per-
oxide, and superoxide anion.The protein was then placed on
ice, protected from light to prevent possible damaging pho-
toreactions.When indicated, CBS p.P49L was incubated with
AdoMet for ≥10 minutes, prior to reduction with 90 𝜇M
sodium dithionite. CO association kinetics were studied by
mixing in the stopped-flow apparatus reducedCBS p.P49L, in
the absence or presence of AdoMet, with CO solutions and
the spectra recorded over time. CO dissociation kinetics were
evaluated by mixing the Fe(II)-CO adduct of CBS p.P49L
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with NO∙ stock solutions, prepared by equilibrating degassed
ultra-pure water with NO∙ gas at 1 atm, further kept on ice
protected from light.
2.5. Spectral Data Analysis. CO affinity titrations and CO
binding and dissociation kinetic data were analyzed with
the software MATLAB (Mathworks). Global fit analysis of
spectral data was performed by singular value decomposition
analysis combined with curve fitting [52].
2.6. Protein Crystallization. Initial crystallization screenings
for CBSΔ 409–551 p.P49L were performed in 96-well plates at
293K using a Cartesian mini-Bee nanoliter-drop dispensing
robot (Genomic Solutions). These screenings allowed for the
identification of one hit for CBSΔ 409–551 p.P49L from the
JCSGplus screen (MolecularDimensions): G10 (0.15MKBr,
30%w/v PEG 2000MME). Crystals were optimized at the
microliter scale using sitting-drop vapor diffusionwith a drop
composition of 0.5𝜇l protein solution (27.4mg⋅ml−1 in buffer
Awith 20𝜇MPLP) and 0.5 𝜇l reservoir solution (0.15MNaBr,
35% PEG 2000MME) equilibrated against 500 𝜇l precipitant
solution in thewell. Dark orange colored small needles as well
as big rod-shaped crystals appeared after 12 h at 20∘C.
2.7. Data Processing and Refinement. Cryoprotection condi-
tions for diffraction experiments were achieved by transfer-
ring the crystals to a 5 𝜇l drop of 35% (w/v) PEG 2000MME,
5% (v/v) glycerol, and 0.15M NaBr. The crystals were flash-
cooled by quick plunging into liquid nitrogen. A single crystal
was used for data collection under a nitrogen-gas stream
(Oxford Cryosystems 700) on beamline ID30A-3 at the ESRF
synchrotron (Grenoble, France) using a PILATUS 6M detec-
tor (Dectris) at a wavelength of 0.9677 Å. After indexing and
calculation of a data collection strategy using EDNA [53], a
wedge of 360∘ of data was collected using a fine-slicing
strategy (0.1∘ rotation per image). The data set was indexed
and integrated with XDS [54], the space group assignment
was performed with POINTLESS [55], and scaling was per-
formed with AIMLESS [56], all within the autoPROC data-
processing pipeline [57]. At this stage an 𝑅free-flag set was
created corresponding to 5% of the measured reflections of
the data set. Crystals belonged to the monoclinic space group
P1 with unit cell parameters 𝑎 = 86.2 Å, 𝑏 = 86.8 Å, 𝑐 =
97.8 Å, 𝛼 = 102.6∘, 𝛽 = 103.1∘, and 𝛾 = 111.2∘. Data were
truncated at 2.80 Å. Data reduction and refinement statistics
are depicted in Table 1. The structure of the CBSΔ 409–551
p.P49L variant was solved by molecular replacement using
PDB entry 1JBQ devoid of any solvent and cofactors as search
model using phaser [58] within the PHENIX software suite of
programs [59]. Based on the Matthews coefficient, the search
was performed for six molecules. Automated model building
was performed using the AutoBuild wizard [60], also within
PHENIX. Initial refinement rounds were carried out with
BUSTER-TNT [61] using the macro that accounts for missing
parts of the model (“-L”). At this point, electron density
features attributed to the hememoietieswere easily identified.
Iterative cycles of manual model building and refinement
were carried out with COOT [62] and BUSTER-TNT until










𝑎, 𝑏, 𝑐 (Å) 86.2, 86.8, 97.8
𝛼, 𝛽, 𝛾 (∘) 102.7, 103.1, 111.2
Resolution rangea (Å) 76.35–2.80 (2.90–2.80)
Total number of reflections 121227 (1141)
Number of unique reflections 58862 (571)
Completeness (%) 98.5 (95.6)
Multiplicity 2.1 (2.0)
⟨𝐼/𝜎(𝐼)⟩ 4.8 (1.5)
𝑅measb (%) 17.4 (68.7)
𝑅pimc (%) 11.2 (45.1)
𝐶𝐶1/2d (%) 97.6 (62.1)
Wilson 𝐵-factor (Å2) 41.8
Refinement
𝑅cryste (%) 18.2 (27.2)
𝑅freef (%) 22.1 (33.1)




r.m.s.d bonds (Å) 0.010
r.m.s.d. angles (∘) 1.12
Protein residues 2077
Ramachandran plot
Most favoured (%) 96.6
Allowed (%) 3.2
Outliers (%) 0.3






aInformation in parenthesis refers to the last resolution shell. b𝑅meas =
Σℎ𝑘𝑙(𝑛/𝑛 − 1)
1/2Σ𝑖|𝐼ℎ𝑘𝑙,𝑗 − ⟨𝐼ℎ𝑘𝑙,𝑗⟩|/Σℎ𝑘𝑙Σ𝑗𝐼ℎ𝑘𝐼,𝑗, where 𝑛ℎ denotes multi-
plicity and 𝑗 the𝑗-th reflection ℎ𝑘𝑙. c𝑅pim = Σℎ𝑘𝑙(1/𝑛 − 1)
1/2Σ𝑖|𝐼ℎ𝑘𝑙,𝑗 −
⟨𝐼ℎ𝑘𝑙, 𝑗⟩|/Σℎ𝑘𝑙Σ𝑖𝐼ℎ𝑘𝐼,𝑗, where 𝑛ℎ denotes multiplicity and j the j-th reflection
ℎ𝑘𝑙. d𝐶𝐶1/2 is as described previously [69].
e𝑅cryst = ∑ℎ𝑘𝑙 ‖𝐹obs(ℎ𝑘𝑙)| −
|𝐹calc(ℎ𝑘𝑙)‖/∑ℎ𝑘𝑙 |𝐹obs(ℎ𝑘𝑙)|, where 𝐹obs(ℎ𝑘𝑙) and 𝐹calc(ℎ𝑘𝑙) are the observed
and calculated structure factors for reflection (ℎ𝑘𝑙), respectively. f𝑅free was
calculated as 𝑅cryst but using only 5% of reflections randomly selected
and omitted from refinement. gMolProbity score provides a single number
that represents the central MolProbity protein quality statistics; it is a log-
weighted combination of Clashscore, Ramachandran not favored, and bad
side-chain rotamers, giving one number that reflects the crystallographic
resolution at which those values would be expected.
convergence. Validation was performedwithRAMPAGE [63]
andMolProbity [64] as implemented in PHENIX.
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PLP-“untreated”


































Figure 1: Hydrogen sulfide production byWT and p.P49LCBS.H2S
producing activity of CBS purified in the absence (PLP-“untreated”)
or presence (PLP-“treated”) of PLP (20𝜇M). 𝑇 = 37∘C. Buffer:
50mM KPi, 300mM KCl, 10% glycerol, 100 𝜇M EDTA, pH 7.0.
Reaction mixture contained 50𝜇MPLP, 0.4–2.0mM homocysteine,
260U/ml catalase, and 10mM cysteine. Assays were carried out in
the absence (−) or presence (+) of 500 𝜇MAdoMet.
3. Results
3.1. Hydrogen Sulfide Synthesis by CBS p.P49L. H2S synthesis
by the CBS p.P49L variant using homocysteine and cysteine
as substrates was analyzed in comparison with the WT
enzyme by amperometric and colorimetric (lead acetate)
methods. Two sets of enzyme preparations, purified either in
the absence or in the presence of the PLP cofactor, were
evaluated in assays run in the presence of PLP. As shown
in Figure 1, the p.P49L CBS variant isolated in the absence
of PLP (PLP-“untreated”) displays a basal activity more
than 3-fold lower than that of the WT enzyme. Despite the
markedly impaired enzymatic activity of “untreated” CBS
p.P49L, activity stimulation by AdoMet is similar between
WT and p.P49L (respectively, 1.5- and 1.4-fold). Conversely,
the p.P49L CBS variant purified in the presence of PLP
(PLP-“treated”) displays a basal activity similar to the WT
enzyme, despite presenting impaired activity stimulation
by AdoMet (1.9-fold for WT to be compared with 1.1-
fold for p.P49L). The AdoMet activation factor (≤2-fold)
observed for the WT enzyme was slightly lower than usually
reported (2–5-fold). This could be related to a fraction of the
enzyme lacking the C-terminal domain, which was also
observed for the CBS p.P49L variant (see Supplementary
Figure S1 in the Supplementary Material available online at
https://doi.org/10.1155/2017/8940321).
3.2. Structure of CBS p.P49L Variant. In an attempt to
understand the structural impact of the proline-to-leucine
substitution at position 49 of human CBS, we have deter-
mined the X-ray structure of a truncated form of the
p.P49L variant (PDB entry 5MMS), lacking the C-terminal
143 residues (henceforth designated as CBSΔ 409–551 p.P49L),
similarly to the reported structure of truncated WT CBS
(PDB entry 1JBQ) [65]. Crystals belong to the triclinic space
group P1 with cell dimensions 𝑎 = 86.2, 𝑏 = 86.8, and 𝑐
= 97.8 Å, 𝛼 = 102.6∘, 𝛽 = 103.1∘, and 𝛾 = 111.2∘. XDS as
implemented in autoPROC clearly identifies two different
lattices in the diffraction pattern rotated by 121.4∘ relative to
each other.This diminishes the quality of the overall statistics
since in some directions an almost perfect superposition of
reflectionsmakes the integration difficult (data collection and
refinement statistics are depicted in Table 1).
There are six molecules in the asymmetric unit corre-
sponding to a Matthews coefficient [66] of 2.31 Å3⋅Da−1 and
a solvent content of approximately 47%. The structure was
refined to 2.80 Å resolution with 𝑅cryst of 18.2% and 𝑅free of
22.1%. The final model comprises the residues from R45 to
E400 (in chain D), 6 hemes, 6 PLP molecules, 3 sodium ions,
and 185 water molecules. The hemes are axially bridged by
C52 and H65 and the PLP moieties covalently linked to the
polypeptide chain through K119. The maps are generally of
good quality except for two disordered loops (T193 to S199
and Q295 to T300), for which only in chain D there were
complete electron densities.This contrasts with the published
structure of the truncated human CBS WT (PDB entry
1JBQ), where the T193-S199 loop could not be modeled. The
variant dimeric structure, shown in Figure 2(a), displays an
essentially identical overall fold with respect to the WT
enzyme (r.m.s.d. of 0.4 Å for 344 aligned C𝛼 carbon atoms
between chainD of CBSΔ 409–551 p.P49L and chain A of 1JBQ)
and highly conserved features in the PLP active site and the
N-terminally located heme moiety (Figure 2(b)).
3.3. Spectral Properties of Ferrous p.P49L CBS. In the absence
of clear structural clues for pathogenicity of the p.P49Lmuta-
tion, we sought to evaluate by UV-visible absorption spec-
troscopy the impact of this residue substitution on the protein
redox spectra, largely dominated by the heme absorption. In
WT CBS, heme reduction leads to notable changes in the
protein absorption spectrum, with a shift of the Soret band
from 428 nm to 449 nm (Figure 3(a)). Upon incubation of
the enzyme with AdoMet prior to reduction, the spectrum of
the reduced enzyme is affected by a decrease in the 449 nm
band intensity and the appearance of a feature centered at
∼424 nm (Figure 3(a), red solid line). Regardless of AdoMet,
in the oxidized state, p.P49L CBS exhibits no differences in
the absorption spectrum as compared to the WT protein
(Figure 3, dashed lines). In contrast, major differences can
be noted by comparing the spectra of the two proteins in
the reduced state, with the mutant displaying markedly
more pronounced appearance of the 424 nm spectral feature
and decrease of the 449 nm band (Figure 3(b), blue solid
line), both further elicited in the AdoMet-bound protein
(Figure 3(b), red solid line).
3.4. Enhanced Affinity of p.P49L CBS for CO. Prompted by
the observed spectral differences between reduced p.P49L
andWT CBS, we analyzed the affinity of the mutated protein











Figure 2: Structure of CBS p.P49L. X-ray crystallographic structure of CBSΔ 409–551 p.P49L solved at 2.80 Å resolution (PDB entry 5MMS). (a)
Cartoon representation of the protein dimer, each monomer being represented in a different color. Pyridoxal 5󸀠-phosphate (PLP) and heme
moieties shown in stick representation. (b) Structure superposition of CBSΔ 409–551 p.P49L (PDB entry 5MMS) and truncatedWT CBS (PDB
entry 1JBQ), both colored in grey except for most relevant regions and residues, where CBSΔ 409–551 p.P49L is colored in red and CBSΔ 409–551
WT in blue; zoom in on the PLP and hememoieties, highlighting the proline-to-leucine substitution, as well as the R266 residue and 𝛼-helix 8
proposed to mediate communication between the heme and the PLP active site. Figure generated with PyMOL 1.8.2 (The PyMOLMolecular
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Figure 3: Absorption spectra of WT and p.P49L CBS. Absorption spectra of WT (a) and p.P49L (b) CBS (1.4–1.6 𝜇M in heme) recorded
at 20∘C, in degassed buffer A (50mM KPi, 300mM KCl, 10% glycerol, 100𝜇M EDTA, pH 7.0), containing glucose oxidase (4 units⋅ml−1),
catalase (13𝜇g⋅ml−1), superoxide dismutase (12 units⋅ml−1), and glucose (3mM). Spectra were collected in the oxidized state (dashed lines)
and upon protein reduction (solid lines) by addition of 90𝜇M sodium dithionite, in the absence (blue lines) and presence (red lines) of
AdoMet (500𝜇M). Arrows highlight direction of the spectral changes caused by AdoMet in the reduced proteins.
for the physiologically relevant CO ligand by performing
anaerobic CO titrations. Similarly to the WT protein, con-
version of ferrous CBS p.P49L to the CO adduct resulted in
the appearance of a band centered at 422 nm (Figures 4(a) and
4(b)).Global fit analysis of the spectral data set acquired along
the titration revealed a much higher CO affinity (>50-fold)
of p.P49L CBS (Figure 4(c), full circles) as compared to the
WT enzyme (Figure 4(c), dotted line). Notably, as previously
reported by Vicente et al. [20] for WT CBS (Figure 4(c),
dashed line) and consistent with the effect of AdoMet on the
spectrum of reduced p.P49L CBS (Figure 3(b)), preincuba-
tion of the protein variant with AdoMet further enhances
the CO affinity (Figure 4(c), hollow squares). CO titrations
allowed us to estimate the following 𝐾𝑑 values: 𝐾𝑑CO,1 =
0.06 ± 0.03 𝜇M and 𝐾𝑑CO,2 = 21 ± 5 𝜇M (with 60% and
40% relative amplitude, respectively) for AdoMet-free p.P49L
CBS and 𝐾𝑑CO,1 ≤ 0.03 𝜇M and 𝐾𝑑CO,2 = 1.5 ± 0.6 𝜇M
(with 70% and 30% relative amplitude, respectively) for the
AdoMet-bound enzyme. It should be noted that the CO
affinity of the AdoMet-bound p.P49L variant is so high that
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Figure 4: Enhanced CO affinity of p.P49L CBS. Absorption spectra collected upon anaerobic titration of reduced CBS p.P49L (1.4–1.6𝜇M
in heme) with CO, in the absence (a) or presence (b) of AdoMet. 𝑇 = 20∘C. (c) Titration profiles obtained by global fit of the spectral data
acquired in the absence (full circles) or presence (hollow squares) of 500𝜇MAdoMet. Data were best fitted according to (1), yielding 𝐾𝑑CO,1
= 0.05 𝜇M (60%) and 𝐾𝑑CO,2 = 22.0 𝜇M (40%) for AdoMet-free CBS p.P49L and 𝐾𝑑CO,1 ≤ 0.03 𝜇M (70%) and 𝐾𝑑CO,2 = 2.1 𝜇M (30%) for the
AdoMet-bound enzyme.Gray lines represent titration curves for WT CBS in the absence (dotted line) and presence (dashed line) of 500𝜇M
AdoMet.
the𝐾𝑑CO,1 value actually represents an upper limit. A possible
direct interference of CO with AdoMet was ruled out by
performing a control experiment where an AdoMet solution
was equilibrated with CO gas (or N2 as control), yielding no
spectral changes (not shown).
3.5. Kinetics of CO Binding and Dissociation from p.P49L
CBS. The markedly higher CO affinity of p.P49L CBS as
compared to the WT enzyme led us to investigate by time-
resolved absorption spectroscopy the kinetics of CO binding
to and dissociation from ferrous p.P49LCBS (Figure 5). Upon
stopped-flowmixing reduced CBS p.P49Lwith 1mMCO, the
observed spectral changes were identical in shape to those
shown for the CO titrations in Figure 4, that is, the predom-
inant 449 nm Soret band and the 424 nm spectral feature
both shifted to 422 nm, with similar optical transitions for the
AdoMet-free and AdoMet-bound CBS p.P49L (inset to Fig-
ure 5(a)). Global fit analysis of the kinetic data revealed that
both AdoMet-free and AdoMet-bound p.P49L react with
CO according to multiphasic time courses (Figure 5(a)), as
previously shown for WT CBS [19, 20, 51, 67]. Interestingly,
despite the markedly increased CO affinity of p.P49L with
respect to the WT protein, under identical experimental
conditions CO binding to the either of the two proteins in
the absence of AdoMet proceeds at comparable rates (t1/2
= 26.2 ± 9.6 s for CBS p.P49L, Figure 5(a), to be compared
with 𝑡1/2 = 34.5 ± 10.5 s of WT, not shown). In the presence
of AdoMet, where the spectral changes (Figure 3) and the
enhanced CO affinity (Figure 4) of CBS p.P49L point to
significant effects on the heme properties, a marked increase
in CO association rates is observed, with t1/2 decreasing to 5.4± 3.1 s (Figure 5(a)), to be compared with t1/2 = 17.0 ± 2.7 s for
WT CBS (not shown).














































Figure 5: Kinetics of CO binding to ferrous CBS p.P49L. (a) Reaction time courses measured in the absence (dotted line) or presence of
AdoMet (500 𝜇Mbefore mixing; solid line). Spectral data collected after stopped-flowmixing 1mMCOwith reduced CBS p.P49L (1.5 𝜇M in
heme) at 25∘C, in 50mM potassium phosphate, 300mM KCl, 10% glycerol, pH 7.0, containing 2mM glucose, 4 units⋅ml−1 glucose oxidase,
13 𝜇g⋅ml−1 catalase, and 6 units⋅ml−1 superoxide dismutase. Fitted rate constants (% reaction amplitude): k1 = 0.48 s−1 (25%), k2 = 0.05 s−1
(30%), and k3 = 0.006 s−1 (45%) for AdoMet-free CBS p.P49L (t1/2 = 19.5 s) and k1 = 2.55 s−1 (35%), k2 = 0.26 s−1 (30%), and k3 = 0.022 s−1
(35%) for the AdoMet-bound enzyme (t1/2 = 2.3 s). Inset, optical transitions obtained by global fit analysis of the spectral data acquired in the
absence (dotted line) or presence of AdoMet (solid line). (b) Time courses of CO displacement from ferrous CBS p.P49L by 900𝜇M NO∙,
acquired in the absence (dotted line) or presence of AdoMet (solid line; 500𝜇M before mixing). Traces were best fitted with the following
rate constants (% reaction amplitude): k1 = 1.93 s−1 (75%) and k2 = 0.035 s−1 (25%) for AdoMet-free CBS p.P49L; k1 = 1.96 s−1 (75%) and k2
= 0.038 s−1 (25%) for the AdoMet-bound enzyme. Inset, optical transitions obtained by global fit analysis of the spectral data acquired in the
absence (dotted line) or presence of AdoMet (solid line).
The kinetics of CO dissociation from CBS p.P49L was
evaluated by anaerobically mixing in the stopped-flow appa-
ratus the CO-bound ferrous protein with authentic NO∙
(900 𝜇M after mixing) and monitoring the conversion of the
422 nm hexacoordinate CO-bound adduct spectrum into
that of the pentacoordinate NO∙-bound adduct with a broad
absorption band centered at 395 nm (inset to Figure 5(b)).
Global fit analysis of the kinetic data revealed that under
identical experimental conditions CO is displaced by NO∙
in CBS p.P49L at comparable rates (k1 = 2.0 ± 0.1 s−1 and
k2 = 0.37 ± 0.05 s−1, with 75% and 25% relative amplitude,
respectively) to the WT enzyme (k1 = 2.0 ± 0.1 s−1 and k2
= 0.33 ± 0.03 s−1, with 75% and 25% relative amplitude,
respectively; data not shown), showing no effect of AdoMet
(Figure 5(b)).
4. Discussion
Classical homocystinuria is an inborn error of metabolism
associatedwith deficiency in cystathionine𝛽-synthase (CBS),
a key enzyme in the transsulfuration pathway of methionine
metabolism. By catalyzing the conversion of homocysteine
and serine into cystathionine, the enzyme prevents an exces-
sive increase in homocysteine levels, a pathological condition
associated with oxidative stress and clinical complications
in the vascular, neurological, and skeletal systems. CBS also
has a relevant role in human physiology by being a major
source of H2S, a key endogenous signaling molecule whose
dysregulation is at the basis of several human patholo-
gies, from cardiovascular and neurodegenerative diseases to
cancer. Thus far, despite decades of research on classical
homocystinuria, a full understanding of themolecular events
at the basis of the pathogenicity of several CBS mutations
remains elusive, although protein misfolding, dysfunctional
regulation by AdoMet, and impaired enzymatic activity have
been put forward for some mutations [15, 28, 33–39].
This prompted us to investigate in the present study a
reportedly mild pathogenic mutation associated with clas-
sical homocystinuria, a proline-to-leucine substitution at
residue 49 in human CBS [44–46]. The recombinant CBS
p.P49L variant was expressed in E. coli, purified, and charac-
terized both structurally and functionally. In line with previ-
ous reports focused on the canonical cystathionine synthase
activity, this variant displayed a H2S synthesizing activity
remarkably sensitive to PLP supplementation along the
purification procedure [36, 37, 39, 40]. The functional rescue
of p.P49L H2S synthesis by PLP is indicative of a decreased
affinity of this variant for the cofactor, a frequently observed
consequence of missense mutations potentially associ-
ated with protein misfolding. The functional recovery of
p.P49L observed upon PLP supplementation during protein
purification was however not fully matched in terms of activ-
ity stimulation byAdoMet, as theH2S-synthesizing activity of
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p.P49L showed poor responsiveness to AdoMet (Figure 1) as
compared to its cystathionine synthase activity [36, 37, 39,
40]. This is not surprising since for other CBS variants it
has been shown that the extent of the stimulatory effect
of AdoMet can differ between the canonical cystathionine
synthase and the H2S-synthesizing activities [28].
Further attempting to understand the molecular basis of
pathogenicity of this mutation, the crystallographic structure
of a truncated form of the CBS p.P49L variant (CBSΔ 409–551
p.P49L) was obtained at 2.8 Å resolution and compared
with that of the truncated WT enzyme (PDB 1JBQ) [65].
Within the obtained resolutions, the structures display highly
conserved features (Figure 2), particularly inspecting the PLP
binding pocket with the cofactor covalently bound to K119,
the heme ligands C52 and H65, 𝛼-helix 8 (responsible for the
heme-PLP communication), the R266 residue forming a salt-
bridge with C52, and the flexible loop where the mutated P49
residue is located.Therefore, at first glance, the structural data
do not seem to provide a clue for the pathogenicity of the
mutation.
The effect of the mutation on the spectroscopic and
ligand-binding properties of the heme moiety was also
investigated. The first hint for a perturbation in the CBS
p.P49L hememicroenvironment arose from inspection of the
dithionite-reduced spectrum of this protein variant (Fig-
ure 3). Indeed, in the spectrum of reduced CBS p.P49L, the
dominating 449 nm band assigned to the hexacoordinate
ferrous heme with C52 and H65 as axial ligands shows
a significant intensity decrease as compared to the WT
enzyme and the appearance of a band at 424 nm (Figure 3(b)).
The latter spectral feature has been assigned to a ligand
exchange process in CBS leading to formation of an enzy-
matic species (called C-424), in which the cysteine thiolate
ligand is replaced by a neutral species [14, 15], negatively
impacting the enzymatic activity. In WT CBS, this ligand
exchange process occurs very slowly (>48 h at 37∘C, [14]) in
the presence of excess reductant. Similarly to p.P49L, other
CBS variants have been previously reported to display an
increased propensity to form the C-424 species, particularly
CBS variants withmutated residues in𝛼-helix 8 [28]. Further-
more, as observed for the WT CBS (Figure 3(a)), incubating
the p.P49L variant with AdoMet prior to reduction further
enhances the conversion of the “normal” 449 nm into the
ligand-exchanged C-424 species in the reduced protein (Fig-
ure 3(b)). Interestingly, among the several CBS variants stud-
ied by Yadav and coworkers [28], p.T257V shows the most
similar spectra to CBS p.P49L and, like this variant, it displays
WT-like (and PLP-dependent) H2S-generating activity and
impaired activation by AdoMet [28]. Altogether, the spectral
data herein reported point to changes at the heme moiety of
CBS p.P49L that were further explored by evaluating the CO
binding properties of the protein variant. CBS has been
shown to be inhibited in vitro by exogenous ligands like CO
andNO∙ [16–20], with different lines of evidence pointing to a
physiological relevance of this regulatory mechanism in vivo
[21–27] (see below).
By performing CO titrations under anaerobic conditions,
we observed spectral changes (Figure 4) consistent with the
formation of the hexacoordinate ferrous-CO adduct, with
the C52 thiolate or the yet unknown “X” ligand of the C-
424 species being replaced by CO, and the heme retaining
the H65 endogenous ligand. Notably, the CO affinity, herein
measured for the first time in a CBS variant, is markedly
increased (≥50-fold) in CBS p.P49L with respect to the WT
enzyme (Figure 4(c), [16, 20, 51]). As previously described for
WT CBS, the CO titrations followed a biphasic profile, which
has been previously attributed to heterogeneity in the heme
microenvironment [16] or anticooperativity between hemes
within a CBS dimer [51]. The remarkably higher CO affinity
of CBS p.P49L is essentially due to the extremely low 𝐾𝑑CO,1
(0.06 ± 0.03 𝜇M), close to the detection limit of the exper-
imental setup. Notably, and as previously observed for the
WT enzyme [20], incubation of CBS p.P49L with AdoMet
induced a further increase in CO affinity (Figure 4(c)) and,
therefore, only an upper limit value for 𝐾𝑑CO,1 (≤0.03 𝜇M)
could be estimated. In the WT enzyme, the increased
CO affinity observed in the presence of AdoMet is fully
matched with an enhanced propensity for CO inhibition of
the protein H2S producing activity [20]. Based on the
remarkable increase in CO affinity herein documented for
CBS p.P49L, this protein variant is expected to be more
prone to inhibition at low physiological CO levels. This may
represent a more general mechanism of pathogenesis in
classical homocystinuria, if other pathogenic CBS mutations
will be demonstrated to lead to enhanced CO affinity, as
shown for CBS p.P49L in the present study.
Although direct evidence for ferrous CBS formation in
vivo is still missing in the literature, several reports have
attested the physiological role of CBS inhibition by CO
(reviewed in [26, 27]), which requires the heme to be
in the ferrous state. Regarding regulation of cerebral micro-
circulation by hypoxia, decreased oxygen levels impair CO
production by heme oxygenase HO-2 and the release of
CBS inhibition by CO promotes H2S synthesis that in turn
mediates vasodilation of precapillary arterioles [23]. Stress-
inducible levels of CO in mice liver cause metabolomic
changes consistent with CBS inhibition, decrease in hepatic
H2S, and concomitant stimulation of HCO3
−-dependent bile
output in wild type, but not in heterozygous CBS knock-
out mice [22]. Another proposed mechanism concerns the
CO-mediated regulation of glucose utilization, where CBS
inhibition by CO drives the demethylation of phosphofruc-
tokinase/fructose bisphosphatase type-3 (PFKFB3), diverting
glucose from the glycolytic towards the NADPH-generating
pentose phosphate pathway, with implications in chemore-
sistance and oxidative stress resistance in cancer cells [24].
Moreover, Kabil et al. [25] have recently shown that, under
endoplasmic reticulum stress conditions, CBS inhibition by
CO, combined with CSE induction, flips the CSE substrate
preference from cystathionine to cysteine, transiently stim-
ulating H2S production. These multiple lines of evidence
provide compelling though still indirect evidence for the
formation of ferrous CBS in vivo. In line with these obser-
vations, an NADPH-dependent diflavin enzyme, methionine
synthase reductase, has been shown to reduce the CBS
heme in vitro in the presence of CO or nitrite, generating,
respectively, the ferrous-CO or ferrous-NO CBS adducts [18,
67, 68]. In light of this evidence, the high affinity of CBS






















Figure 6: Increased flexibility of the heme binding loop in p.P49LCBS. Representation of𝐵 factor variation along the structure of CBS p.P49L
(PDB entry 5MMS) andWT (PDB entry 1JBQ) monomer, displaying in first plane the regions encompassing the proline-to-leucine mutation
(sticks) and the heme ligands C52 and H65. Flexibility can be visualized both by the thickness of the structural element and the respective
color: highest flexibility represented in red (hot) thick elements; lowest flexibility in thin blue (cold) elements (color scale: red > orange >
yellow > green > blue). Figure generated with PyMOL 1.8.2 (The PyMOLMolecular Graphics System, Version 1.8 Schrödinger, LLC).
p.P49L for CO is fully compatible with the formation of the
ferrous-CO adduct at physiological CO concentrations.
To gain mechanistic insight into this high CO affinity, we
studied by stopped-flow absorption spectroscopy the kinetics
of CO association/dissociation to/from the reduced heme of
this protein variant (Figure 5). Similarly to theWT [19, 20, 51],
CO binding to reduced CBS p.P49L followed a multiphasic
time-course (Figure 5(a)). Taking into account the markedly
increased CO affinity of this protein variant, surprisingly the
reaction proceeded only slightly faster (t1/2 = 26.2 ± 9.6 s)
than for the WT enzyme (t1/2 = 34.5 ± 10.5 s) under identical
experimental conditions. Despite thisminor difference, in the
presence of AdoMet the fold increase in the CO association
rate was overall higher in the p.P49L variant (∼4.5-fold) than
in the WT enzyme (∼2-fold) under identical experimental
conditions. Furthermore, by analyzing the kinetics of CO
replacement by NO∙ in this protein variant, we observed
essentially identical kinetic traces for the AdoMet-free and
AdoMet-bound CBS p.P49L (Figure 5(b)) and for the WT
enzymeunder the same experimental conditions (not shown).
The kinetics of CO association and dissociation therefore
do not provide a clear cut explanation for the markedly
higher CO affinity of CBS p.P49L, which requires further
inspection. In Scheme 1 are represented the reaction steps for
conversion of the hexacoordinate ferrous CBS, with the heme
Fe ligated to H65 and either C52 or the unknown “X” ligand
in the C-424 species, into the ferrous-CO adduct. It has been
previously postulated for theWTenzyme that COassociation
to the ferrous CBS heme is rate-limited by dissociation of
C52 [19, 20, 51]. Since we observed similar CO associa-
tion kinetics for WT and p.P49L, where a fraction of the
mutant enzyme is likely to be in the ligand-exchanged C-424
state, the CO association appears to be limited by the off-
rate of the endogenous ligand regardless of its nature, C52
or “X” (𝑘off ,Cys/X (p.P49L) ≈ 𝑘off ,Cys/X (WT) in Scheme 1). Taking
into account the fact that the kinetics of CO dissociation
were almost identical for WT and p.P49L CBS, regardless
of AdoMet being present (𝑘off ,CO (p.P49L) ≈ 𝑘off ,CO (WT) in
Scheme 1), the dramatic increase in CO affinity of the
p.P49L variant compared to the WT should be related to
a slower rebinding of the endogenous ligand, C52 or “X”
(𝑘on,Cys/X (p.P49L) ≪ 𝑘on,Cys/X (WT) in Scheme 1), and/or a
faster combination of CO with the transiently generated
pentacoordinate species (𝑘on,CO (p.P49L) ≫ 𝑘on,CO (WT) in
Scheme 1).
Regardless of these mechanistic details, the perturbed
spectrum of the reduced protein and its remarkably higher
affinity for CO point to possibly subtle structural changes in
the CBS p.P49L variant affecting heme reactivity. To this end,
we further compared the structures of the variant and WT
enzymes in terms of local flexibility evaluated based on the B
factor (Figure 6). This analysis interestingly reveals that the
differences in flexibility are mostly located in specific regions
of the protein.The𝛼-helix 8,where somemutations have been
shown to affect the heme spectral properties and the H2S-
generating activity similarly to p.P49L, displays comparable
rigidity between CBS p.P49L and the WT enzyme. We thus
looked in greater detail at the heme binding region (Figure 6)
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and found in CBS p.P49L an increased flexibility of the
loop surrounding the C52 ligand, which expands to the
regions between the C52 and H65 ligands and even after the
latter residue. The p.P49L structure therefore displays a
higher flexibility in the region harboring both heme ligands,
which provides a possible structural basis for the proposed
slower rebinding of the endogenous C52/X ligands upon CO
dissociation, thereby accounting for the increased affinity of
CBS p.P49L for CO.
5. Conclusions
Cystathionine 𝛽-synthase (CBS) is a key enzyme in the
transsulfuration pathway that prevents oxidative stress con-
ditions, both controlling homocysteine levels and promoting
the expression of antioxidant enzymes through the synthe-
sis of H2S. Being implicated in metabolic, oncologic, and
neurodegenerative diseases, CBS is currently recognized as
a promising drug target. Mutations in the CBS gene can lead
to classical homocystinuria, a human disease associated with
oxidative stress that affects the vascular, neurological, and
skeletal systems. Protein misfolding, enhanced propensity to
aggregation, decreased cofactor affinity, and dysfunctional
regulation by the allosteric activator AdoMet, together with
impaired enzymatic activity, have been proposed to account
for the pathogenicity of several CBS mutations. As a novel
finding, herein we reported that a clinically relevant variant
of CBS (p.P49L) has markedly increased affinity for CO,
a known inhibitor of CBS. On this basis, this variant is
expected to be much more prone than WT CBS to be
inactivated by CO at the physiological levels occurring in
vivo, thereby contributing to pathogenicity. The enhanced
affinity for inhibitory gaseous ligands documented here may
represent a new pathogenic mechanism at the basis of CBS-




CBSΔ 409–551: Truncated cystathionine 𝛽-synthase
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